VivoSeq
Other

Locally Advanced

0

Pipeline Programs↗

47

Active Trials↗

19

Companies Involved↗

Locally Advanced is an early-stage landscape with 0 programs across 19 companies. The most active players are Roche, AstraZeneca, Blueprint Medicines.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalB

Blueprint Medicines

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalR

Rainier Therapeutics

0 programs

PreclinicalI

ImmuneOncia Therapeutics Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

156

clinical trials

Completed53 · 34%
Unknown status30 · 19%
Recruiting27 · 17%
Terminated20 · 13%
Active, not recruiting11 · 7%
Not yet recruiting9 · 6%
Other6 · 4%

Clinical Trials

Trial Activity

156 trials

Tumor Treating Fields for Locally Advanced NSCLC
Recruiting·UUniversity of Utah·Phase 1·NCT06124118·30 enrolled
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Recruiting·TTang-Du Hospital·Phase 2·NCT07353723·10 enrolled
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Recruiting·EEye & ENT Hospital of Fudan University·Phase 3·NCT06235203·154 enrolled
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Recruiting·IImmuneOncia Therapeutics Inc.·Phase 2·NCT06365840·30 enrolled
MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
Recruiting·FFudan University·Phase 2·NCT07235566·60 enrolled
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT06254521·60 enrolled
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Recruiting·AAvacta Life Sciences Ltd·Phase 1·NCT07454642·144 enrolled
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Recruiting·UUniversity of Chicago·Phase 4·NCT02366819·36 enrolled
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Recruiting·—·Phase 3·NCT06791512·166 enrolled
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT06601309·90 enrolled
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Recruiting·EEmory University·Phase 2·NCT06006013·21 enrolled
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Recruiting·PPeking University·Phase 2·NCT06023758·18 enrolled
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04165772·200 enrolled
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Recruiting·FFudan University·Phase 2·NCT05628922·198 enrolled
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
Recruiting·—·Phase 2·NCT06808971·61 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)